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ABSTRACT 
A simple, accurate and selective colorimetric method was developed and validated for determination of five of 1,4-
dihydropyridine drugs (1,4-DHP) using tetrabutylammonium hydroxide reagent (TBAH). The proposed method was based 
on addition of TBAH to the studied drugs then the produced yellow colors were measured spectrophotometrically. Different 
variables which affecting the reaction conditions were carefully studied and optimized. Under the optimum conditions, 
Beer's law was obeyed in the concentration range of 2.50-40.0 µg/mL and the limits of detection were ranged from 0.750-
1.956 µg/mL. The proposed method was successfully extended to the pharmaceutical preparations, tablets and capsules.  
The obtained results were comparable with that obtained by the reference methods.  
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INTRODUCTION 
Hypertension or high blood pressure is a cardiac chronic condition in which the systemic arterial blood pressure is 
elevated. It is classified either a primary (essential) hypertension or secondary hypertension. About 90-95% of cases are 
categorized as primary hypertensive and the remaining 5-10% of cases are secondary hypertensive patients. Although the 
dietary and lifestyle changes can improve the blood pressure and decrease the risk of associated health complications, 
but drug treatment may be necessary in patient for whom lifestyle changes are ineffective or insufficient. 
Calcium ions play an important role in function of cardiovascular system and the calcium channel blockers (CCB) primarily 
exert their activities through inhibiting the calcium ion entry into the cells. Also CCB affect the cardiac and vascular smooth 
muscle cells and cause vasodilatation for both coronary and peripheral arteries, hence reducing the blood pressure [1, 2]. 
Nifedipine (NIF), nicardipine (NIC), nimodipine (NIM), felodipine (FEL) and amlodipine (AML), Figure 1 are the prototypical 
1,4-DHP derivatives and they are considered as CCB agents. Furthermore, they are useful in other pathological states, 
such as seizures and central ischemic disorders [3]. 
 
Fig 1.Chemical structures of the investigated 1,4-DHP drugs 
Detailed survey of literatures for NIF revealed that several UV-Visible spectrophotometry methods that have been reported 
for its assay either alone or in combination with other drugs [4-13]. But only a few spectrophotometric and 
spectrofluorimetric methods have been reported for determination of NIC [10, 11,13-17]. NIM has another advantage than 
other its members, it is recommended for improvement of neurological outcomes by reducing the incidence and severity of 
ischemic deficits in patients with subarachnoid hemorrhage [18, 19]; for its assay a different spectrophotometric methods 
have been described in the present literatures [10, 11, 19-25]. In the quantitative determination of FEL in pharmaceutical 
dosage forms, spectrometric methods have been published [10, 11,26-29]. Also AML has been assayed in its pure and 
pharmaceutical dosage forms using different spectrometric methods [10, 11, 16, 30-51]. 
The main goal of this work is to establish a simple, accurate, precise, and reproducible spectrophotometric method for 
determination of these drugs in bulk and in their pharmaceutical preparations. Further, the established method should be 
rapid and economic to be applied for the routine quality control analysis or in pharmaceutical dosage forms. 
EXPERIMENTAL 
Instrumentation:  
Absorbance measurements were made on Shimadzu-1601UV-Visible Spectrophotometer (Shimadzu, Tokyo, Japan), 
Jenway-6305 UV-Visible Spectrophotometer (Jenway LTD, U.K). 
Reagents and solutions: 
A 25 mg/mL of TBAH (Sigma Chemical Co., St. Louis, USA) solution was prepared in dimethylsulphoxide (DMSO) (Laba 
Chemie, Mumbai, India). Reference standards of pure drugs (NIF, NIC, NIM, FEL, AML and other combined drugs such as 
atenolol and metoprolol) were generously supplied from their respective manufacturers. 0.5 mg/mL of stock standard were 
prepared in DMSO; the working standard solutions were prepared by further dilution with DMSO. 
Procedure for calibration curves: 
An aliquot of 1.0 mL of the standard or sample solution was transferred into 10 mL calibrated flask. 1.0 mL of TBAH was 
added; the reaction was allowed to proceed for 20 min then diluted to the mark with DMSO. The absorbance of the 
resulting yellow color solutions were measured at 432, 447, 458, 457 and 464 nm for NIF, NIC, NIM, FEL, and AML 
respectively, versus experimental blank treated similarly. 
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Pretreatment procedure for the assay of tablets and capsules: 
The contents of twenty tablets or capsules were mixed thoroughly and quantities of the powder equivalent to 50 mg of the 
active ingredient were dissolved in 50 mL DMSO. The contents were swirled and sonicated for 5 min then the mixture was 
filtered. The collected filtrate was transferred into 100 mL calibrated flask and completed to the mark with DMSO. 
Pretreatment procedure for the assay of tablet and capsule containing two drugs: 
Twenty tablets (Logimax
®
 tablets, FEL and metoprolol) or capsules (Tenolat SR
®
 capsules, NIF and atenolol) were 
weighted accurately and the contents were mixed thoroughly. Quantities of the powder equivalent to 50 mg of the active 
ingredient of NIF and FEL were dissolved in 50 mL DMSO then the procedure was completed as the previous. 
RESULTS AND DISCUSSION 
The proposed method was focused on treatment of 1,4-DHP drugs with TBAH base in DMSO. Figure 2 (AML, as a 
representative example) illustrates the bathochromic shift of the colored chromogen from the original spectrum of AML. 
Through the literatures; the corresponding anions of dihydropyridine are prepared by reaction of Hantzsch type 
dihydropyridines moiety with a strong base in a non-polar solvent, but unfortunately, nothing is known about  the site of 
protonation, i.e. those have electron withdrawing substituents in both 3 and 5 positions [52, 53]. Exploratory experiments 
for such compound showed that the nature of the protonated species depended upon both the solvent and the base 
strength [54]. J. Luis et al. [55] explained the addition of TBAH base to 1,4-DHP drugs in DMSO produces a drastic 
bathochromic shift that is due to anion formation in the basic medium utilizing the proton in 1,4-DHP ring and the band 
gradually disappeared after addition of perchloric acid solution. Subsequently, as Figure 3 shows, we verified this 
suggested neutralization reaction after color formation. 
 
Fig 2. Absorption spectra of AML, 20 µg/mL and its colored product after addition of TBAH 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3. Absorption spectra of (1) AML, 20 µg/mL (2) AML after addition of TBAH (3) AML and TBAH reaction 
product after addition of 0.1 M perchloric acid, 1.0 mL 
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OPTIMIZATION OF PARAMETERS: 
Different variables such as type and concentration of the alkali, reaction time, temperature, and the diluting solvent, which 
influencing the intensity of the colored products were studied and optimized.  
Basic reagent and organic solvents system: 
Preliminary experiments were carried out to select the type of alkali and the organic medium; the results that were 
obtained revealed that the highest reaction products chromogen achieved when TBAH used compare to other used alkali 
such as NaOH, KOH and tetraethylammonum hydroxide solution. The greatest colors were obtained in dipolar aprotic 
solvents such as acetone, dimethyl formamide (DMF) or DMSO and the formed colors intensity increased relatively by 
increasing in dielectric constant of these solvents (20.7, 36.71 and 46.68 for acetone, DMF and DMSO, respectively [56]). 
Water and other protic solvent such as ethanol, methanol and propanol have a destructive effect on the formed 
chromogen. Therefore the highest and the stable absorption intensity for the produced colored products were observed 
when TBAH/DMSO system was used. 
TBAH concentration: 
25 mg/mL TBAH regent was selected from different studied concentrations ranged from 10-45 mg/mL of TBAH, Figure 4. 
 
Fig 4. Effect of TBAH concentration on the absorption intensity of the reaction products with 1,4-DHPs, 20 µg/mL 
Reaction time: 
The reaction between drugs and TBAH was completed after 20 min at room temperature (25±5
 o
C) and the absorbance 
values of the colored products remained stable for more than 30 min after their dilution, Figure 5. 
 
Fig 5.Time effect on the color intensity of the reaction products of TBAH with 1,4-DHP, 20 µg/mL 
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REACTION STOICHIOMETRY 
Job's method of continuous variation [57] was employed to establish the stoichiometry of proposed method. The ratios 
between the investigated drugs and TBAH were 1:2; Figure 6 using NIF as representative example. 
 
Fig 6. Job’s plot for the reaction TBAH with NIF 
Suggested reaction between the studied drugs and NBS: 
Based on previous literatures, our experimental finding and the calculated molar ratios we suggested that the reaction 
mechanism is anion formation between acidic N-H and TBAH, as illustrated in Scheme 1. The aromatization of the 1,4-
DHP ring is difficult under this conditions; that was established by the destructive effect of perchloric acid on the developed 
chromogen. The new finding in this study is the negative effect of nitro group on the reaction pass-way as it was reported 
in the previous explanations [6, 32,58]. 
 
Scheme 1. The suggested reaction pathway of reaction between 1,4-DHP and TBAH 
 
VALIDATION OF PROPOSED METHODS 
The developed procedures were fully validated according to USP XXVI [59] validation guidelines and International 
Conference on Harmonization (ICH) guidelines [60].  
Linearity range, detection and quantification limits: 
Calibration curves for the investigated drugs with TBAH method constructed by analyzing a series of different 
concentrations of the drug standard solutions. Linear relationships were found between the measured values of the 
absorbance intensities and the concentrations of the investigated drugs as indicated by the high correlation coefficients 
obtained (r), in the concentrations were ranged from 2.50-40.0 μg/mL. The limit of detection (LOD) and limit of quantitation 
(LOQ) were determined according to the IUPAC definitions [61] using the formula LOD or LOQ = SDa/b; where  = 3 for 
LOD and 10 for LOQ, SDa is the standard deviation of the intercept and b is the slope. The regression equations for the 
results derived using the least square method and the obtained results summarized in Table 1. 
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Table 1. Quantitative parameters and statistical data for the proposed method 
Drug 
Linear range 
μg/mL 
r Regression equation
1
 
LOD 
Μg/mL 
LOQ 
μg/mL 
*10
4
          
l/mol/m 
NIF 2.5-35 0.996 y= 0.023x + 0.015 1.956 6.521 0.893 
NIC 2.5-35 0.996 y= 0.021x + 0.010 0.750 2.500 1.137 
NIM 5.0-40 0.999 y= 0.021x + 0.009 1.280 4.285 0.939 
FEL 2.5-30 0.997 y= 0.031x + 0.014 1.354 4.516 1.370 
AML 2.5-35 0.996 y= 0.024x + 0.010 1.125 3.751 1.460 
 
1
y: absorbance and x: Sample conc., µg/mL     
*
: The molar absorptivity 
 
Precision and accuracy: 
The proposed method’s precision was determined by carrying out replicate analysis of five separated solutions of the 
working standards at one concentration level. The relative standard deviations (RSD) of the results did not exceed 2%, for 
intra- and inter-day precision indicating a good repeatability and reproducibility with acceptable accuracy of the proposed 
method. Table 2 
Table 2. Assay of five replicate samples of the studied drugs by TBAH at one concentration level 
Drug  Conc., µg/mL 
Accuracy % 
(n-5) 
Precision RSD (%) 
(n=5) 
Intra-day Inter-day 
NIF 20 91.1±0.004 0.38 1.6 
NIC 25 96.4±0.003 0.73 1.8 
NIM 15 100.0±0.004 0.63 1.2 
FEL 20 95.1±0.003 0.53 1.4 
AML 02 101.4±0.003 0.39 1.5 
 
Robustness and Ruggedness 
The proposed method’s robustness was examined by evaluating the influence of small variation in some experimental 
parameters on its suitability and specificity. The changed parameters were the concentration of TBAH and the reaction 
time. It was found that none of these variables significantly affect the original data of the proposed method, Table 3.  
Table 3. Robustness of the proposed method 
 Recovery % ± SD
a
 
Variation NIF
b
 NIC
b
 NIM
b
 FEL
b
 AML
b
 
No variation 98.34±0.23 97.21±0.24 98.38±0.25 99.30±1.25 99.22±0.26 
TBAH conc.  
        24.75 mg/mL 99.40 ± 1.23 98.20 ± 1.12 97.27 ± 1.28 99.52±1.20 99.20±0.26 
        25.25 mg/mL 98.24 ± 1.22 98.11 ± 0.34 98.19 ± 0.47 99.23±1.14 99.51±1.18 
Reaction time   
         19 min 98.27±1.34 98.20±0.21 99.37±0.81 99.31±0.77 99.65±1.36 
          21 min 99.25±1.22 98.43±0.13 98.27±0.87 99.34±0.36 99.89±0.56 
a
Values are the mean of three determinations ± SD     
b
Drugs conc., 20 µg/mL 
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The proposed method’s ruggedness was tested by applying the assay of the investigated drugs using the same conditions 
but using two different instruments at two different laboratories and different elapsed time, the results obtained were found 
to be reproducible as RSD did not exceed 2%, Table 4. 
Table 4. Ruggedness of the proposed TBAH method 
Drugs
b
 
Recovery % ± SD
a
 
Instrument Inter-day variation 
Shimadzu Jenway Day-1 Day-2 Day-3 
NIF 99.24±0.89 99.21±1.24 98.32±0.23 97.22±1.56 99.62±0.51 
NIC 99.66±1.17 99.99±1.18 97.27±0.24 99.08±1.35 98.81±0.44 
NIM 99.92±1.27 99.10±0.66 98.30±0.13 99.24±1.33 98.40±0.69 
FEL 98.17±1.22 99.11±0.18 99.13±1.25 98.51±0.56 98.49±1.56 
AML 99.29±1.83 98.15±1.88 99.02±0.26 97.29±1.34 98.41±1.34 
a
Values are the mean of three determinations ± SD                    
b
Drugs conc., 20 µg/mL 
Selectivity of the proposed method 
The selectivity of the method was checked by monitoring a standard solutions of the drugs in the presence of other 
ingredients which present in the tablets and capsules, such as atenolol or metoprolol with NIF and FEL, respectively or 
excipients [62], the response was not different from that obtained in the calibration curves. 
Application of the proposed method 
Tablets and capsules were subjected to analysis for their contents from 1,4-DHP drugs using the proposed method, Table 
5. The results were compared with those obtained from either official [63] or reported methods [14, 40], with respect to the 
accuracy (t-test) and precision (F-test). No significant differences were found between the calculated and theoretical 
values of t- and F-tests at 95% confidence level proving similar accuracy and precision in the analysis of the investigated 
drugs in their dosage forms. 
Table 5. Determination of the studied drugs in their tablets and capsules using TBAH and official or reported 
methods 
Product 
Recovery % ± SD
a
  
F-value
b
 
 
t-value
b
 Proposed method Official or reported method
c
 
Epilate
® 
capsules 97.43±0.12 99.52±0.11 2.98 1.67 
Epilate Retard
® 
tablets 99.45±0.17 98.51±0.13 2.13 1.20 
Tenolat SR
® 
capsules* 97.21±0.12 100.52±0.66 1.81 1.61 
(Pelcard SR
® 
capsules)
c
 98.56±0.02 99.74±0.11 1.62 2.24 
Nimotop
® 
tablets 99.48±0.15 98.61±0.19 1.49 1.93 
Plendil
® 
tablets 97.69±0.10 99.24±0.13 2.64 1.67 
Plentopine
® 
tablets 97.52±0.15 99.22±0.11 1.62 1.18 
Logimax
® 
tablets* 99.31±0.18 99.34±0.17 1.12 0.36 
(Alkapress
® 
tablets)
c
 98.40±0.19 99.21±0.12 4.69 1.80 
(Myodura
® 
tablets)
c
 98.24±0.13 98.31±0.11 1.39 0.16 
(Amlodipine
® 
tablets)
c
 99.23±0.11 97.20±0.12 1.00 1.23 
(Regcor
® 
tablets)
c
 99.39±0.12 99.24±0.16 1.14 0.20 
(Vasonorm
® 
tablets)
c
 98.33±0.16 98.41±0.19 1.14 0.17 
a
Mean of five determinations  
b
Theoretical values for F and t at 95% confidence limit (n = 5) were 6.39 and 
2.78, respectively.   
c
Reported methods [14, 40] *Drugs that present in combination 
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CONCLUSION 
A yellow color that formed under the above mentioned conditions measured spectrophotometrically can be regarded as 
anion formation between acidic N-H in 1,4-DHP drugs and TBAH alkali. The new finding in this study is the negative effect 
of nitro group on the reaction pass-way as it reported in the previous explanations. The proposed method have the 
advantages of simplicity, sensitivity, selectivity and reproducibility, which satisfies the need for a rapid procedure for routine 
determination of 1,4-DHP drugs in bulk or in their dosage forms.  
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